Asymmetric Synthesis and Chemical Biology

San Diego, CA
Joined June 2017
We did a thing! pubs.rsc.org/ob/article/doi/… This review, which is part of a themed collection on axially chirality, was written with the goal of sharing some fundamentals and capturing a 'snapshot' of the state of atropisomerism in drug discovery.
1
4
30
1,653
One thing worth mentioning is the majority of examples utilized tried and true chiral resolution chemistry, however there was a lot of innovation in recycling of the unwanted atropisomer. There were also a few examples of asymmetric catalysis being employed.
1
1
119
We hope people find this useful, and it helps stimulate discussion and thought on how best to set atropisomeric axes in practical settings.
33
Excited to announce that the preliminary program for the 2027 Gordon Research Conference on Heterocyclic Compounds, June 20–25 in Newport, RI, is online! grc.org/heterocyclic-compoun… We have an outstanding lineup of academic and industry scientists. Hope to see many of you there!
6
21
1,425
You forgot to mention the PhD's beat the PhD Candidates in volleyball
a successful beach day (most) of the organic chemistry groups along with a PhDs vs Candidates volleyball match! (a few injuries, no deaths) @GustafsonLab @jillalty @barneygrubbs @QJBruch Prof. Katherine Aubrecht and Prof. Matthew Parkers Group
1
3
1,102
The R-atropisomer* maintained potency against cellular models of GIST (IC50 < 10 nM) while displaying improved target selectivity, including towards key oncogenic c-KIT mutants. *Cahn-Ingold-Prelog priorities cause the analogs to have opposite stereochemical descriptors.*
1
1
229
The S-Atropisomer* had no KIT activity, but displayed intriguing selectivity towards LYN kinase, an emerging target for the treatment of cancer, autoimmune diseases and inflammatory conditions, that currently lacks highly selective inhibitors.
176
The ‘conformational mapping’ of diarylamine crystal structures suggested that the pan-HER kinase inhibitor neratinib adopts two planar conformations around a C–N axes (similar to cis and trans alkenes). HER family kinases generally preferred the ‘trans’ conformation
1
5
371
This led us to introduce a peri Fluoro group as a H-bonding handle to ‘lock’ that axis into the trans conformation. This seemingly simple modification led to a dramatic increase in HER selectivity, particularly towards HER4, a kinase with emerging implications in ovarian cancer.
3
248
Gustafson Group @ Stony Brook retweeted
Our department (@StonyBrookChem) is looking for a PRODiG+ fellow – the appointment is two years, followed by conversion to a tenure-track assistant professor at the conclusion of the fellowship. A unique opportunity! apply.interfolio.com/178732
1
8
1
27
3,928
Reposting. One more week until the deadline!
The Stony Brook Chemistry Department is searching for a Chemical Biologist at the Associate or Full professor Level. Come join us on Long Island and do some great science! apply.interfolio.com/174211
1
749
Gustafson Group @ Stony Brook retweeted
Doctor Gavin Rustin we salute you
Check out our latests work in collaboration with @Taylorlab_Chem ! We evaluated their biomolecular photocaged trifluormethylation reagent on small molecules, finding it effected the rapid trifluoromethylation of diverse aromatics, including several APIs. chemrxiv.org/engage/chemrxiv…
4
26
4,813
Check out our latests work in collaboration with @Taylorlab_Chem ! We evaluated their biomolecular photocaged trifluormethylation reagent on small molecules, finding it effected the rapid trifluoromethylation of diverse aromatics, including several APIs. chemrxiv.org/engage/chemrxiv…
2
4
3
57
7,453
The Stony Brook Chemistry Department is searching for a Chemical Biologist at the Associate or Full professor Level. Come join us on Long Island and do some great science! apply.interfolio.com/174211
2
5
1,432
Gustafson Group @ Stony Brook retweeted
Professor Jeff Gustafson (Stony Brook University, @GustafsonLab) (gustafsongroup.sdsu.edu/word…) presented the Organic Syntheses Lecture at Notre Dame on September 24th, 2025.
3
1
26
2,955